Fosun Pharma Unit Wins China Trial Nod for Novel Alopecia Biotherapeutic

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).

Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai MicroH Therapeutics, has received approval from China’s National Medical Products Administration to conduct a clinical trial of LBP-ShC4, a live biotherapeutic product for treating androgenetic alopecia. The company plans to initiate Phase I clinical research in mainland China once the necessary conditions are met, building on prior approval for the same indication from the U.S. Food and Drug Administration in 2025.

LBP-ShC4 is independently developed within the Fosun Pharma group, underscoring the company’s push into innovative dermatology and hair-loss treatments, an area with significant commercial potential. As of February 2026, Fosun has invested about RMB20 million in the candidate’s R&D, signaling a growing commitment to microbiome-based therapies that could enhance its competitive position in both domestic and international pharmaceutical markets if clinical results prove successful.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare conglomerate engaged in pharmaceutical manufacturing, medical services, medical devices and diagnostics, and other healthcare-related businesses. The group focuses on innovative drug research and development and operates through both domestic and overseas subsidiaries to expand its footprint in key therapeutic areas.

YTD Price Performance: -2.81%

Average Trading Volume: 3,051,437

Technical Sentiment Signal: Sell

Current Market Cap: HK$71.82B

For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.